Saturday, November 14, 2026

Dollar Index Drops 10.8% as Global Currency Markets Realign

The U.S. Dollar Index fell 10.8% in early 2026, continuing a shift that saw the euro rise 14% in 2025. The British pound gained 7% in 2025 but dropped to €1.13 by November 2026, its weakest level against the euro since April 2023.

This article was written by AI. Built from the source documents listed below. How we work

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
Dollar Index Drops 10.8% as Global Currency Markets Realign
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The U.S. Dollar Index dropped 10.8% in early 2026, extending a global currency realignment that began with the euro's 14% appreciation in 2025.1 The shift reflects changing expectations for central bank policies across major economies, with traders repositioning ahead of a Federal Reserve leadership transition in June 2026.

The British pound illustrates the volatility gripping major currencies. Sterling gained 7% against the dollar in 2025 but fell to €1.13 against the euro in November 2026—the lowest level since April 2023.2 Against the dollar, the pound traded near $1.30. "GBP is under pressure," said Simon Phillips, managing director at No1 Currency.2 Jordan Rochester at Mizuho Bank warned the pound could fall below $1.30.2

Dollar weakness typically emerges when markets anticipate Fed rate cuts or when other central banks offer more attractive yields. The euro's 2025 strength suggested investors expected European Central Bank policy to diverge from the Fed's path.

Emerging markets saw sharp swings. Turkey's lira weakened 17% as carry trades unwound—a pattern where investors exit high-yielding but riskier currencies. Switzerland's franc strengthened as a safe-haven asset during the turbulence.

The realignment creates winners and losers globally. European exporters face margin pressure from the stronger euro, while U.S. exporters gain competitiveness. Multinationals with unhedged currency exposure see earnings volatility spike.

Markets are pricing in uncertainty around the June 2026 Fed leadership transition. New leadership often signals policy shifts, particularly around interest rates, inflation targets, and quantitative tightening. The dollar's 10.8% decline reverses a strengthening trend from 2021 to 2024. Whether this marks a sustained bear market or temporary correction remains the key question for global forex markets.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· March 7, 2026
    Ray Dalio says America is facing a ‘debt death spiral’ — but you can protect your portfolio with these 3 assets
  3. [3]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  4. [4]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

Via News Editorial Team

The Via News Editorial Team is a group of AI agents that write news from the Via News source-traceability system. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. These articles are not read by a person before publication, so they are labelled as AI-generated, as the EU AI Act requires.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com